Jan Erik Schow, MD
Adult Medicine · Garland, UTNPI 1215922919
Payments from drug & device makers
Across 271 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$732
- Johnson & Johnson$609
- AbbVie$591
- AstraZeneca$475
- Amarin Pharma, Inc.$334
- Novartis$197
- plus $1K from 30 others
What the payments were for
- Food & beverage$4,305100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 35 | $732 |
| Johnson & Johnson(2 entities) | 41 | $609 |
| AbbVie(2 entities) | 46 | $591 |
| AstraZeneca | 26 | $475 |
| Amarin Pharma, Inc. | 24 | $334 |
| Novartis | 14 | $197 |
| Lilly USA, LLC | 10 | $147 |
| Pfizer | 9 | $135 |
| Amgen | 8 | $133 |
| Abbott | 5 | $104 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $95 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| Novo Nordisk | 6 | $84 |
| Merck | 4 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $36 |
| GSK | 2 | $36 |
| Sanofi Pasteur Inc. | 2 | $35 |
| Eisai Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| QOL Medical, LLC | 1 | $25 |
| Seqirus USA Inc | 1 | $23 |
| Dexcom, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Philips North America LLC | 1 | $13 |
| Lucid Diagnostics Inc. | 1 | $13 |
How this compares
Too few adult medicine providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 104 | $130,667 |
| OzempicSemaglutide | 111 | $119,806 |
| EliquisApixaban | 99 | $94,203 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 55 | $71,364 |
| XareltoRivaroxaban | 44 | $62,628 |
| TrulicityDulaglutide | 52 | $60,974 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 150 | $32,376 |
| MounjaroTirzepatide | 25 | $30,587 |
| FarxigaDapagliflozin Propanediol | 19 | $25,893 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 59 | $18,406 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,729 |
| JanuviaSitagliptin Phosphate | 18 | $6,505 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $6,469 |
| Gabapentin | 212 | $5,144 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 154 | $4,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $732 | $130,667104 claims |
| Novo NordiskOzempic | $84 | $119,806111 claims |
| PfizerEliquis, Abrysvo, Paxlovid | $135 | $114,038170 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $147 | $91,56177 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $18 | $73,58468 claims |
| Johnson & JohnsonXarelto | $609 | $62,62844 claims |
| GSKShingrix | $36 | $32,376150 claims |
| AstraZenecaFarxiga, Symbicort | $475 | $28,46330 claims |
| MerckJanuvia | $54 | $6,50518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Utahon file to place this against a meaningful peer group, so we don't.
Other adult medicine in Garland
- Kimberlie YadonRiverton$909
- Lisa HansonSouth Jordan$364
- Nathan EliasonMurray$323
- Steven RouzerMoab$76
- Jessica FecteauHyde Park$53
- Chaseton WomackProvo$3
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.